Calling all Bioanalysts: We’re Making Bioanalytical Selectivity Challenges History

Apr 17, 2018 | Biopharma, Blogs, Pharma | 0 comments

High selectivity is a key component of successful quantitative bioanalysis. As a bioanalyst, we need consistently accurate and robust quantitation of small molecule therapeutics and metabolites. Challenged by complicated matrix interferences, high baseline signal, and lack of isomer resolution, we need to embrace innovative strategies to increase the sensitivity and selectivity of our assays. If our ‘go-to’ is the development of complex HPLC conditions or modifying sample preparation procedures, we will find ourselves bogged down with time-consuming methods that reduce sample throughput. So, what’s the answer?

Imagine a new dimension in bioanalytical selectivity that you never thought possible. One that enables robust and reproducible bioanalytical methods, and meets high throughput requirements. One that reduces background noise, eliminates interferences and separates highly similar compounds, without having to resort to complex HPLC conditions or sample workup procedures.

Well this could very much be your reality.

Significant advances have been made in increasing MS/MS selectivity beyond the gold standard MRM. For example, MRM3 on the QTRAP® systems adds additional selectivity by increasing the number of fragmentation steps by the mass analyzer. Ion mobility presents another attractive option by introducing an orthogonal level of separation after sample ionization, followed by traditional m/z detection.

Although ion mobility techniques have been used extensively for qualitative applications, they have traditionally lacked the required ruggedness and speed required for quantitative bioanalysis. Not anymore, and hereby the end of the history lesson!

SelexION® DMS Technology provides an orthogonal level of separation. It is the first differential ion mobility separation technology to combine sensitivity and selectivity with unmatched reproducibility and robustness. It delivers enhanced analytical separations on demand for isobaric species and co-eluting contaminants, all in an elegantly simple package.

Along with the QTRAP 6500+ or 5500 systems, you get the power of differential ion mobility separation, enabled by multiple new innovations in ion mobility:

  • The introduction of chemical modifier adds a new dimension to selectivity and dramatically increases separation capacity.
  • Planar geometry results in high speed and minimal diffusion losses for maximum sensitivity and UHPLC compatibility.
  • Highly robust, reproducible, and stable for use in regulated bioanalysis.
  • Easy to maintain, and can be Installed or removed in minutes with no need to break vacuum on the mass spectrometer, or use any tools.

Do you want to know more? We thought you might, so we have developed some tech notes to support you in your quest to achieve high performing small molecule therapeutics and metabolite quantitation workflows in drug discovery and development:

  • SelexION Technology: A New Solution to Selectivity Challenges in Quantitative Bioanalysis
  • Separation of Diastereomeric Flubatine Metabolites using SelexION Technology
  • Improving Multiple Reaction Monitoring (MRM) Selectivity for Mesalamine with the SelexION differential mobility separation device

If you are challenged by complex small molecule therapeutics and metabolite quantitation requiring advanced analytical selectivity, look no further. Download the eBook and get access to these technical papers, and so much more. Find out about The Science Behind SelexION Differential Ion Mobility Technology and how SeleXION Addresses Your Biggest Analytical Challenges.Download the eBook >

PFAS testing: 2024 in review and what to expect for 2025

For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.

Inside the box: Acoustic ejection mass spectrometry for drug discovery

On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.

Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024

In a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial